Robert W. Baird cut shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) from a neutral rating to an underperform rating in a report issued on Tuesday. Robert W. Baird currently has $408.00 price objective on the biopharmaceutical company’s stock.

“nothing to scoff at,” Skorney said in his downgrade note. However, investor expectations for a strong performance has “stretched the valuation beyond what is reasonable” based on the initial launch metrics (see Skorney’s track record here).In fact, investor expectation shifted from “high” in late April/May to “extraordinary” today, the analyst added. Meanwhile, buy-side analysts may have also gotten ahead of themselves in predicting Dupixent to outperform Novartis’ blockbuster therapy, Cosentyx.”We believe shares reflect a greater degree of optimism than is warranted,” Skorney emphasized. “We continue to believe Dupixent will be a big drug, as reflected by our reiterated target price of $408.,” Robert W. Baird’s analyst commented.

A number of other research firms also recently weighed in on REGN. Leerink Swann reissued an outperform rating and set a $573.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 22nd. Raymond James Financial, Inc. reissued an outperform rating and set a $547.00 target price (up from $475.00) on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 22nd. Bank of America Corporation reissued a buy rating and set a $593.00 target price (up from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. BMO Capital Markets reissued a market perform rating and set a $484.00 target price (up from $421.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. Finally, BidaskClub raised shares of Regeneron Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Saturday, June 24th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $489.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 1.41% during trading on Tuesday, reaching $466.59. The company had a trading volume of 495,953 shares. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $543.55. The company has a market capitalization of $49.47 billion, a price-to-earnings ratio of 46.81 and a beta of 1.66. The company has a 50-day moving average price of $495.54 and a 200 day moving average price of $426.50.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The firm had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. During the same period in the prior year, the firm earned $2.82 EPS. The company’s revenue was up 21.2% compared to the same quarter last year. Analysts expect that Regeneron Pharmaceuticals will post $14.84 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://theolympiareport.com/2017/08/12/robert-w-baird-downgrades-regeneron-pharmaceuticals-inc-nasdaqregn-to-underperform.html.

In related news, SVP Robert E. Landry sold 526 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $472.19, for a total value of $248,371.94. Following the transaction, the senior vice president now owns 9,099 shares in the company, valued at approximately $4,296,456.81. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Sanofi bought 136,050 shares of the firm’s stock in a transaction that occurred on Friday, June 2nd. The stock was acquired at an average price of $478.17 per share, for a total transaction of $65,055,028.50. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 56,922 shares of company stock worth $27,383,105. Corporate insiders own 10.40% of the company’s stock.

A number of institutional investors have recently modified their holdings of REGN. Alpha Windward LLC boosted its position in shares of Regeneron Pharmaceuticals by 0.3% in the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 1 shares during the last quarter. Concert Wealth Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 0.4% in the first quarter. Concert Wealth Management Inc. now owns 723 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 3 shares during the last quarter. Cleararc Capital Inc. boosted its position in shares of Regeneron Pharmaceuticals by 0.3% in the first quarter. Cleararc Capital Inc. now owns 1,850 shares of the biopharmaceutical company’s stock worth $717,000 after buying an additional 5 shares during the last quarter. Regentatlantic Capital LLC boosted its position in shares of Regeneron Pharmaceuticals by 0.9% in the second quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock worth $264,000 after buying an additional 5 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 1.4% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 750 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 10 shares during the last quarter. Institutional investors own 66.70% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.